Iron / TIBC / Sat: What Your Numbers Change About Your Treatment

What the Iron Panel Actually Measures

The iron panel is three numbers that answer three different questions. Serum iron reflects the amount of iron currently circulating bound to transferrin. TIBC measures how much iron transferrin could carry if fully loaded. Transferrin saturation is serum iron divided by TIBC, expressed as a percentage, and it is the single most clinically actionable number of the three.

Serum Iron

Serum iron fluctuates significantly across a single day. Levels can drop by as much as 30% from morning to afternoon, which is why fasting morning draws are the clinical standard [1]. A result between 60 and 170 mcg/dL is typical for adults, though reference intervals vary slightly by laboratory and sex.

Serum iron alone is rarely sufficient to guide treatment. A person with early iron deficiency can have a normal serum iron reading while transferrin saturation is already sliding downward. Conversely, acute inflammation drops serum iron even when body stores are adequate, a pattern called the anemia of chronic disease.

Total Iron-Binding Capacity

TIBC reflects the total capacity of transferrin to bind iron [2]. When iron stores are low, the liver synthesizes more transferrin, so TIBC rises. When stores are high or inflammation is present, TIBC falls. A TIBC above 450 mcg/dL alongside a low serum iron is a classic iron deficiency pattern. A TIBC below 240 mcg/dL alongside a high serum iron points toward overload or chronic inflammatory suppression.

Transferrin Saturation

Tsat is calculated as: (serum iron / TIBC) × 100. The 2011 AASLD (American Association for the Study of Liver Diseases) practice guidelines specify that a fasting Tsat above 45% on two separate occasions warrants HFE gene mutation testing to evaluate hereditary hemochromatosis [3]. Below 20%, iron delivery to the bone marrow becomes insufficient to support normal erythropoiesis [4].

Normal Ranges and Where the Cutoffs Come From

Reference intervals are not arbitrary. They are derived from population-based studies and calibrated against clinical outcomes, not just statistical distribution.

Adult Reference Intervals

For adults, the widely cited intervals are serum iron 60 to 170 mcg/dL, TIBC 240 to 450 mcg/dL, and Tsat 20 to 45% [5]. The American Association for Clinical Chemistry notes that sex-based differences in serum iron are modest in adults but widen during reproductive years due to menstrual losses [6].

Ferritin is not technically part of the iron/TIBC/Tsat panel, but clinicians order it alongside because ferritin below 30 ng/mL identifies depleted stores even when hemoglobin remains normal. The British Society of Haematology defines iron deficiency anemia as hemoglobin below 13 g/dL in men or 12 g/dL in women combined with ferritin below 30 ng/mL [7].

Pregnancy-Specific Ranges

Plasma volume expands by 40 to 50% during pregnancy, diluting all iron indices [8]. The WHO defines iron deficiency in pregnancy as hemoglobin below 11 g/dL in the first and third trimesters, and below 10.5 g/dL in the second [9]. Tsat below 16% in pregnancy is considered the functional threshold for iron-restricted erythropoiesis by several obstetric guidelines.

Children and Adolescents

Reference intervals shift substantially by age. Tsat below 12% in children aged 1 to 5 years corresponds to iron deficiency in CDC growth monitoring protocols [10]. Pediatric values are outside the scope of this article, which focuses on adult prescribing decisions.

What a Low Iron / TIBC / Sat Result Means for Treatment

Iron deficiency is the most common nutritional deficiency globally, affecting roughly 2 billion people according to WHO estimates [9]. In a telehealth hormone therapy context, it surfaces frequently because the same patients seeking GLP-1 or HRT care often have unrecognized deficiency driving fatigue, brain fog, and poor exercise tolerance.

Diagnosing the Stage of Deficiency

Iron deficiency progresses through three stages [11]:

1. Pre-latent deficiency. Ferritin <30 ng/mL, normal serum iron, normal Tsat, normal hemoglobin. The patient has no anemia but reserves are depleting.
2. Latent iron deficiency. Ferritin <12 ng/mL, Tsat <20%, serum iron low-normal, hemoglobin still normal.
3. Iron deficiency anemia. Hemoglobin below sex-specific thresholds, microcytic hypochromic red cells on CBC differential, Tsat typically <10%.

Identifying which stage the patient is in changes what you prescribe and how fast you expect a response.

Oral Iron Protocols

The 2023 American Society of Hematology (ASH) guidelines recommend oral ferrous sulfate 325 mg (containing 65 mg elemental iron) given on alternate days rather than daily [12]. A randomized trial by Stoffel et al. (N=54) published in The Lancet Haematology found that fractional iron absorption was 40% higher with alternate-day dosing versus consecutive-day dosing, because daily dosing elevates hepcidin for 24 hours and suppresses subsequent absorption [13].

Taking iron with 250 mg of vitamin C increases non-heme iron absorption by up to 67% according to data from the National Institutes of Health Office of Dietary Supplements [14]. Calcium, antacids, and proton pump inhibitors reduce absorption and should be separated by at least two hours.

Expect a hemoglobin rise of approximately 1 to 2 g/dL per month with appropriate oral therapy. Tsat should be rechecked at 4 to 8 weeks. Full repletion of stores, reflected by ferritin above 50 ng/mL, typically requires 3 to 6 months of continued supplementation after hemoglobin normalizes [12].

When IV Iron Is Indicated

Intravenous iron bypasses gastrointestinal absorption entirely. The four main formulations available in the U.S. Are ferric carboxymaltose (Injectafer), ferumoxytol (Feraheme), iron sucrose (Venofer), and low-molecular-weight iron dextran (INFeD) [15]. Each has a different total dose ceiling per infusion and a different adverse event profile.

IV iron is appropriate when:

• Hemoglobin falls below 10 g/dL and the patient is symptomatic.
• Oral iron is not tolerated (gastrointestinal side effects affect roughly 70% of patients on standard doses).
• Malabsorption syndromes such as celiac disease or post-bariatric anatomy prevent adequate oral uptake.
• Functional iron deficiency exists in the setting of erythropoiesis-stimulating agent use or chronic kidney disease.

The FAIR-HF2 trial (N=558), published in The Lancet in 2023, found that IV ferric carboxymaltose reduced the rate of heart failure hospitalizations in patients with heart failure and iron deficiency, with Tsat below 20% or ferritin below 100 ng/mL as enrollment criteria [16].

Iron Deficiency and Hormone Therapy Interactions

Low iron status changes how patients respond to testosterone replacement therapy (TRT) and to GLP-1 receptor agonists.

TRT and iron. Testosterone directly stimulates erythropoiesis by suppressing hepcidin and increasing erythropoietin sensitivity [17]. Starting TRT in a patient with Tsat <20% can produce a brisk rise in red cell production that outpaces available iron, resulting in microcytic erythrocytosis: a high hematocrit built from iron-poor, small red cells. This pattern mimics polycythemia on a CBC but is an artifact of iron-starved erythropoiesis driven by testosterone. Correcting iron deficiency before initiating TRT, or concurrently with it, prevents this scenario.

GLP-1 agonists and iron. Rapid weight loss with semaglutide or tirzepatide reduces caloric intake, which can also reduce dietary iron intake. STEP-1 (N=1,961) demonstrated mean weight loss of 14.9% at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo [18]. Patients losing more than 10% of body weight over 12 months should have an iron panel rechecked because dietary iron intake often drops in parallel with total calories.

HRT and iron. Postmenopausal women no longer lose iron through menstruation, so iron deficiency in this group requires a GI workup to exclude occult bleeding before attributing it to dietary insufficiency.

The HealthRX Iron-Status-Before-Rx Framework stratifies prescribing decisions by Tsat:

| Tsat | Ferritin | Action Before Starting TRT or GLP-1 | |------|---------|--------------------------------------| | <10% | Any | Delay hormone initiation; start IV or high-dose oral iron; recheck in 6 weeks | | 10 to 19% | <30 ng/mL | Start oral iron concurrently; monitor CBC at 8 weeks | | 20 to 45% | >30 ng/mL | Proceed; routine annual recheck | | >45% | Any | Hold hormone therapy pending HFE testing and hepatology referral |

What a High Iron / TIBC / Sat Result Means for Treatment

A fasting Tsat above 45% on two separate morning draws is the established gateway criterion for hemochromatosis evaluation [3]. Hereditary hemochromatosis is among the most common genetic disorders in people of Northern European descent, affecting approximately 1 in 200 to 1 in 300 individuals who are homozygous for the HFE C282Y variant [19].

Confirming the Diagnosis

The diagnostic sequence recommended by the European Association for the Study of the Liver (EASL) in its 2022 Clinical Practice Guidelines proceeds as follows [20]:

1. Fasting Tsat on two separate occasions.
2. HFE genotyping for C282Y and H63D mutations if Tsat is persistently above 45%.
3. Serum ferritin to estimate iron burden.
4. Liver MRI (R2 or T2* sequences) or liver biopsy if ferritin exceeds 1,000 ng/mL to quantify hepatic iron concentration and fibrosis.

A ferritin above 1,000 ng/mL carries a significantly elevated risk of liver fibrosis and warrants hepatology co-management regardless of symptoms [20].

Phlebotomy as the Primary Treatment

Therapeutic phlebotomy remains the first-line treatment for hereditary hemochromatosis. Each 450 to 500 mL whole blood draw removes approximately 200 to 250 mg of elemental iron. The EASL guidelines target ferritin below 50 ng/mL and Tsat below 30% during the depletion phase, with maintenance phlebotomy thereafter to keep ferritin between 50 and 100 ng/mL [20].

Phlebotomy frequency during induction is typically once per week or once every two weeks depending on tolerance and hemoglobin response. Hemoglobin must remain above 11 g/dL before each session to proceed safely.

Iron Overload and Hormone Therapy

High iron loading affects prescribing in several ways. First, testosterone therapy is generally contraindicated when active hemochromatosis is untreated, because testosterone-driven erythropoiesis increases iron utilization transiently but does not eliminate the total body iron burden, and the underlying organ damage from iron deposition in the pituitary, testes, and liver continues [21].

Second, secondary hypogonadism is a recognized complication of iron overload itself. Excess iron deposits in pituitary gonadotrophs, suppressing LH and FSH secretion and causing low testosterone [21]. The American Urological Association's 2018 TRT guideline notes that secondary hypogonadism from systemic disease, including iron overload, should have the underlying condition addressed before TRT is initiated [22].

Third, GLP-1 receptor agonists have no direct interaction with iron metabolism, but patients with hemochromatosis-related liver disease (cirrhosis or advanced fibrosis) require dose-titration caution and closer monitoring of hepatic function during GLP-1 therapy.

How to Raise Transferrin Saturation and Serum Iron

The approach depends entirely on which stage of deficiency is present and whether oral or IV iron is appropriate.

Dietary Sources

Heme iron from red meat, poultry, and seafood has an absorption rate of 15 to 35%. Non-heme iron from legumes, fortified grains, and leafy greens absorbs at only 2 to 20%, depending on enhancers and inhibitors present in the meal [14]. For patients with Tsat in the 10 to 19% range and no symptoms, dietary optimization combined with alternate-day ferrous sulfate is a reasonable starting point.

Oral Supplementation Protocols

The alternate-day dosing protocol from the Stoffel trial applies here [13]. Ferrous sulfate 325 mg on Monday, Wednesday, and Friday mornings with vitamin C, separated from calcium and coffee by two hours. Ferrous gluconate 300 mg (35 mg elemental iron) is better tolerated gastrointestinally and may improve adherence despite slightly lower elemental content.

Reticulocyte count should begin rising within 7 to 10 days of starting iron therapy. If it has not risen by week 3, absorption failure or an alternative diagnosis should be considered [12].

IV Iron for Rapid Repletion

Ferric carboxymaltose 750 mg IV can be given as a single dose (maximum 750 mg per infusion, up to two doses per course) and raises Tsat measurably within 48 to 72 hours as transferrin loading occurs. Ferumoxytol 510 mg IV can be given as two doses 3 to 8 days apart. Both are approved by the FDA for iron deficiency anemia in adults who have an unsatisfactory response to or cannot tolerate oral iron [15].

How to Lower Transferrin Saturation and Serum Iron

Lowering a high Tsat requires removing iron from the body, not just stopping supplementation.

Therapeutic Phlebotomy

This is the treatment for confirmed hemochromatosis. Schedule once-weekly sessions initially, removing 450 to 500 mL per session. Recheck Tsat and ferritin every 10 to 12 phlebotomies during induction. Maintenance phlebotomy every 2 to 4 months sustains target levels long term [20].

Iron Chelation Therapy

Chelation is reserved for patients who cannot tolerate phlebotomy (severe anemia, cardiovascular disease, poor venous access). Deferasirox (Jadenu) 14 to 28 mg/kg/day orally is FDA-approved for chronic iron overload [23]. Deferoxamine (Desferal) 20 to 60 mg/kg/day by subcutaneous infusion is an older option used when oral chelation is contraindicated. Both require monitoring of renal function, liver enzymes, and audiometry.

Dietary Adjustments

Avoiding supplemental vitamin C with meals reduces heme iron absorption modestly. Tea and coffee contain tannins that bind non-heme iron and reduce its uptake. These are supportive measures only, not primary therapy for confirmed overload.

Monitoring Schedule After Treatment Changes

Getting iron status into range is only half the task. Maintaining it requires a structured recheck schedule.

For iron deficiency treated with oral iron: CBC and iron panel at 4 to 8 weeks to confirm response, then at 3 months to confirm hemoglobin normalization, then at 6 and 12 months to confirm store repletion [12].

For iron deficiency treated with IV iron: recheck at 4 weeks post-infusion. Tsat typically peaks at 24 to 48 hours and then redistributes; the 4-week draw reflects true functional repletion better than an immediate post-infusion draw [15].

For hemochromatosis on phlebotomy: Tsat and ferritin before each session during induction, then every 3 months during maintenance. HFE-positive first-degree relatives should be screened with fasting Tsat and ferritin regardless of symptoms [20].

For patients on TRT: baseline iron panel before initiation, then at 3 months, 6 months, and annually thereafter. Hematocrit above 54% is the AUA threshold for phlebotomy or dose reduction in TRT patients [22].

Iron Labs and the Full Hormone Panel Context

Iron status does not exist in isolation. It intersects with thyroid function (hypothyroidism reduces iron absorption), with vitamin D (both deficiencies cluster in the same at-risk populations), and with erythropoiesis broadly.

A patient presenting with fatigue, low libido, and poor exercise tolerance may have low testosterone, iron deficiency, or both. Ordering a full morning panel that includes serum iron, TIBC, Tsat, ferritin, CBC, comprehensive metabolic panel, and a hormone panel (total testosterone, free testosterone, LH, FSH, TSH) at the same draw avoids sequential diagnostic delays.

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states that secondary causes of hypogonadism, including systemic conditions that affect the hypothalamic-pituitary axis, must be identified and treated before testosterone replacement is prescribed [24]. Iron overload damaging pituitary gonadotrophs is one such cause.